Sarepta Therapeutics (SRPT) Riding High On Successful Drug
Tweet Send to a Friend
Down)
Sarepta Therapeutics, Inc. (Nasdaq: SRPT) is higher yet again in pre-open trading Thursday as the company's Duchenne Muscular Dystrophy treatment continues to get positive, tear-jerking press.
Yesterday evening, KFVS Jakson, MO highlighted the case of 12 year old Justin Trovillion. Since he enter the trial for Sarepta's Eteplirsen "Justin has a new energy for life," his mother said. "He is able to do so much more."
Sarepta has seen massive press after one of two Vermont brothers - Austin And Max Leclaire - saw similarly positive results while the other struggled.
Shares of Sarepta, which are up over 200 percent in the last three months, is up another 5 percent in pre-open trading to a new 52-week high of $13.25.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Yesterday evening, KFVS Jakson, MO highlighted the case of 12 year old Justin Trovillion. Since he enter the trial for Sarepta's Eteplirsen "Justin has a new energy for life," his mother said. "He is able to do so much more."
Sarepta has seen massive press after one of two Vermont brothers - Austin And Max Leclaire - saw similarly positive results while the other struggled.
Shares of Sarepta, which are up over 200 percent in the last three months, is up another 5 percent in pre-open trading to a new 52-week high of $13.25.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Can AMD (AMD) Shake Off the Goldman Downgrade?
- Dex Media (DXM) Continues Higher; Up 6%
- UPDATE: Vanda Pharmaceuticals (VNDA) Opens Higher; Lazard Raises PT to $17
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkRelated Entities
Twitter
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
